US EditionPublished • loading... • Updated
Jubilant Therapeutics Inc. appoints Daniel J. O'Connor as President and Chief Executive Officer
Summary by CNHI News
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Jubilant Therapeutics Inc. appoints Daniel J. O'Connor as President and Chief Executive Officer
YARDLEY, Pa., Dec. 5, 2025 /PRNewswire/ -- Jubilant Therapeutics Inc., a clinical-stage biopharmaceutical company developing novel small molecule modulators for oncology and autoimmune diseases, today announced the appointment of Daniel J. O'Connor as President & Chief Executive Officer, effective December…
·United States
Read Full ArticleCoverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
